Abstract
Surgery remains the cornerstone of achieving breast cancer control, but understanding the biological and molecular processes that drive breast cancer development, coupled with the recent advances in therapeutic strategies, have facilitated an individualised approach to disease management. Even in the setting of hereditary breast cancer, risk-reducing surgery and novel targeted therapies have revolutionised management, with this being translated into enhanced oncological outcomes for the majority, including those with advanced disease. The rapidly evolving landscape of breast cancer management makes it imperative that breast surgeons’ knowledge of the biological disease spectrum aligns with contemporary practice. The aim of this review is to provide an update on how molecular cancer profiling influences the management of patients with primary breast cancer.

This publication has 28 references indexed in Scilit: